Mitapivat is highlighted in the EHA 2026 Plenary Abstract Session through S102 RISE UP, evaluating…
Browsing: Life Science
Want to get ideas and solutions for your R&D in Life Science? Check out the resources powered by Patsnap Eureka, find the technical resources you need.
Tafasitamab is highlighted in the EHA 2026 Plenary Abstract Session through S101 frontMIND, evaluating tafasitamab…
Pomalidomide is included in the EHA 2026 entity workbook as an immunomodulatory imide drug (IMiD)…
Daratumumab is included in the EHA 2026 entity workbook as an anti-CD38 monoclonal antibody relevant…
Talquetamab is highlighted in the EHA 2026 Plenary Abstract Session through S100 MonumenTAL-3, evaluating talquetamab…
Ruxolitinib is included in the EHA 2026 entity workbook as a JAK1/2 inhibitor relevant to…
Selinexor is included in the EHA 2026 entity workbook as an XPO1 inhibitor relevant to…
Lenalidomide is included in the EHA 2026 entity workbook as an IMiD relevant to hematology…
SUCCESSOR-2 is an EHA 2026 late-breaking Phase 3 multiple myeloma study, listed as LB5004, evaluating…
Agios Pharmaceuticals is included for EHA 2026 market mapping because its portfolio or pipeline focus…